Gilead Sciences Inc

NASDAQ:GILDUnited States

May 9, 2024

Show headlines and story abstract

• Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program, from 4:05PM ET on Thursday May 09, 2024 by Dow Jones

  4:05PM ET on Thursday May 09, 2024 by Dow Jones
  Companies Mentioned: GILD, ACLX
  
  This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead's ability to realize the anticipated benefits from the collaboration with Arcellx; Gilead and Kite's ability to increase its CAR T-cell therapy manufacturing capacity, timely manufacture and deliver such therapies (or otherwise reduce the time to manufacture such therapies), or produce an amount of supply sufficient to satisfy demand for such therapies, including the production of anito-cel for the iMMagine-3 clinical trial and any future commercial manufacturing; the ability of Gilead and Kite to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical studies, including those involving anito-cel; uncertainties relating to regulatory applications and related filing and approval timelines, including FDA approval of anito-cel for treatment of multiple myeloma; the risk that CAR T-cell therapy will not be broadly accepted by physicians, patients, hospitals, cancer treatment centers, payers and others in the medical community; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements.
  

• Gilead's FOCUS Program Helps Zero In on Early HIV Detection, from 9:46AM ET on Thursday May 09, 2024 by Dow Jones

  9:46AM ET on Thursday May 09, 2024 by Dow Jones
  Companies Mentioned: GILD
  
  NORTHAMPTON, MA / ACCESSWIRE / May 9, 2024 / A 22-year-old college student who didn't feel well was treated at an urgent care facility in Baton Rouge, Louisiana and expected to recover soon. But when his symptoms worsened, he returned to the emergency department and was given a more thorough check-up and routine screening exams - including an HIV test - based on the facility's screening eligibility criteria.